Your browser doesn't support javascript.
loading
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Metzenmacher, Martin; Griesinger, Frank; Hummel, Horst-Dieter; Elender, Corinna; Schäfer, Harald; de Wit, Maike; Kaiser, Ulrich; Kern, Jens; Jänicke, Martina; Spring, Lisa; Zacharias, Stefan; Kaiser-Osterhues, Anja; Groth, Annika; Hipper, Annette; Zaun, Gregor; Dörfel, Steffen; Güldenzoph, Björn; Müller, Lothar; Uhlig, Jens; Thomas, Michael; Sebastian, Martin; Eberhardt, Wilfried E E.
Afiliação
  • Metzenmacher M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
  • Griesinger F; Division of Thoracic Oncology, West German Cancer Center, University Medicine Essen - Ruhrlandklinik, Essen, Germany.
  • Hummel HD; Department of Haematology and Oncology, University Dept Internal Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Oldenburg, Germany.
  • Elender C; Interdisziplinäres Studienzentrum mit ECTU/Translationale Onkologie, Comprehensive Cancer Center, Mainfranken, Universitätsklinikum Würzburg, Würzburg, Germany.
  • Schäfer H; Pneumologie, Infektiologie, Internistische Intensivmedizin, Klinik Nord im Klinikum Dortmund, Dortmund, Germany.
  • de Wit M; Pneumologie, Thorakale Onkologie, Palliativmedizin, Infektiologie, SHG Kliniken Völklingen, Völklingen, Germany.
  • Kaiser U; Klinik für Innere Medizin - Hämatologie, Onkologie und Palliativmedizin, Vivantes Klinikum Neukölln, Berlin, Germany.
  • Kern J; Medizinische Klinik II, Hämatologie & Internistische Onkologie, St. Bernward Krankenhaus, Hildesheim, Germany.
  • Jänicke M; Klinikum Würzburg Mitte - Standort Missioklinik, Med. Klinik mit Schwerpunkt Pneumologie, Würzburg, Germany.
  • Spring L; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
  • Zacharias S; Clinical Epidemiology and Health Economics, iOMEDICO, Freiburg, Germany.
  • Kaiser-Osterhues A; Biostatistics, iOMEDICO, Freiburg, Germany.
  • Groth A; Medical Department, iOMEDICO, Freiburg, Germany.
  • Hipper A; AIO-Studien-gGmbH, Berlin, Germany.
  • Zaun G; AIO-Studien-gGmbH, Berlin, Germany.
  • Dörfel S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
  • Güldenzoph B; Onkozentrum Dresden/Freiberg, Dresden, Germany.
  • Müller L; Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, Germany.
  • Uhlig J; Onkologie Unter Ems, Leer, Germany.
  • Thomas M; Praxis Dr. med. Jens Uhlig, Naunhof, Germany.
  • Sebastian M; Department of Thoracic Oncology, Thoraxklinik, University Hospital Heidelberg and Translational, Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Eberhardt WEE; Department of Hematology and Medical Oncology, University Hospital Frankfurt, Frankfurt, Germany.
Eur Respir J ; 61(2)2023 02.
Article em En | MEDLINE | ID: mdl-36180086
ABSTRACT

INTRODUCTION:

Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care.

METHODS:

Prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models.

RESULTS:

Current M-descriptors of the Union for International Cancer Control-8 staging system were validated M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, p<0.001; PFS HR 1.81, p<0.001). M1b-liver metastases had shorter OS/PFS than M1b involving other organs (OS HR 2.70, p=0.006; PFS HR 2.48, p=0.007). Based on number of involved organs (orgsys) and liver metastases, two risk groups (low-risk M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver; high-risk M1c-liver, M1b-liver, M1c-4+-orgsys) with significantly different prognoses could be amalgamated (median OS/PFS 14.3/6.5 months and 7.7/4.1 months, respectively). Other favourable factors were female gender and Eastern Cooperative Oncology Group stage 0, with age showing no impact. Those with T1- or N0-status were associated with longer OS than T2-4 or N2-3.

CONCLUSION:

In this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha